



This	  is	  an	  author	  version	  of	  the	  contribution	  published	  on:	  
Questa	  è	  la	  versione	  dell’autore	  dell’opera:	  
	  [Autoimmun	  Rev.	  2009	  Jan;8(3):228-­‐32.	  doi:	  10.1016/j.autrev.2008.07.034.]	  
	  
The	  definitive	  version	  is	  available	  at:	  
La	  versione	  definitiva	  è	  disponibile	  alla	  URL:	  
[http://www.sciencedirect.com/science/article/pii/S1568997208001481]	  
CLINICAL	  AND	  GENETIC	  ASPECTS	  OF	  BLAU	  SYNDROME:	  A	  25-­‐YEAR	  FOLLOW-­‐UP	  OF	  ONE	  FAMILY	  AND	  A	  
LITERATURE	  REVIEW	  
Leonardo	  Punzia,	  Antonio	  Furlana,	  Marta	  Podswiadeka,	  Alessandra	  Gavaa,	  Marialuisa	  Valenteb,	  Mario	  De	  
Marchic,	  Andrea	  Pesericod	  
a	  Rheumatology	  Unit,	  Department	  of	  Clinical	  and	  Experimental	  Medicine,	  University	  of	  Padova,	  Italy	  
b	  Department	  of	  Medical	  and	  Diagnostic	  Sciences	  and	  Special	  Therapies,	  University	  of	  Padova,	  Italy	  
c	  Department	  of	  Clinical	  and	  Biological	  Sciences,	  Division	  of	  Medical	  Genetics,	  University	  of	  Torino,	  
Orbassano,	  Italy	  
d	  Department	  of	  Dermatology,	  University	  of	  Padova,	  Italy	  
Keywords	  
Blau	  syndrome;	  Autoinflammatory	  syndromes;	  Granulomatous	  arthritis/rash/uveitis;	  CARD15;	  NOD2	  
Corresponding	  author.	  	  
Prof.	  Leonardo	  Punzi,	  Rheumatology	  Unit,	  Department	  of	  Clinical	  and	  Experimental	  Medicine,	  University	  of	  
Padova,	  Via	  Giustiniani	  2,	  35128	  Padova,	  Italy.	  Tel.:	  +39	  8212190;	  fax:	  +39	  8212191.	  
	  
Abstract	  
Blau	  syndrome	  (BS)	  is	  a	  rare	  familial	  disease	  transmitted	  as	  an	  autosomal	  dominant	  trait,	  characterized	  by	  
arthritis,	  uveitis,	  skin	  rash	  and	  granulomatous	  inflammation.	  Until	  now	  BS	  has	  been	  observed	  in	  136	  
persons	  belonging	  to	  28	  families	  as	  well	  as	  in	  4	  sporadic	  cases.	  The	  gene	  responsible	  for	  BS	  has	  recently	  
been	  identified	  in	  the	  nucleotide-­‐binding	  domain	  (NBD)	  of	  caspase	  recruitment	  domain	  (CARD15/NOD2),	  
also	  involved	  in	  the	  pathogenesis	  of	  Crohn's	  disease.	  In	  addition	  to	  three	  missense	  mutations	  (R334Q,	  
R334W	  and	  L469F)	  previously	  identified,	  a	  new	  CARD	  15	  mutation	  (E383K)	  has	  recently	  been	  described	  in	  a	  
family	  followed	  by	  us	  for	  the	  past	  25	  years.	  The	  characteristics	  of	  this	  family	  which,	  to	  our	  knowledge,	  is	  the	  
only	  one	  affected	  with	  BS	  in	  Italy,	  are	  the	  object	  of	  this	  manuscript.	  Both	  the	  proband	  and	  her	  daughter	  
were	  originally	  affected	  with	  a	  papulonodular	  skin	  eruption	  and	  then	  with	  mild	  arthritis	  of	  the	  hands	  and	  
feet.	  The	  proband,	  but	  not	  the	  daughter,	  complained	  of	  severe	  chronic	  bilateral	  uveitis,	  followed	  by	  
glaucoma	  and,	  a	  few	  years	  later,	  by	  cataracts.	  Histological	  examination	  of	  skin	  biopsies	  from	  both	  subjects	  
and	  a	  joint	  biopsy	  (daughter	  only),	  showed	  non-­‐caseating	  granulomas	  with	  multinucleated	  giant	  cells	  
which,	  at	  electron	  microscopy,	  revealed	  “comma-­‐shaped	  bodies”	  in	  epithelioid	  cells,	  thought	  to	  be	  a	  
marker	  for	  BS.	  The	  disease	  is	  presently	  well	  controlled	  with	  low	  doses	  of	  prednisone	  for	  the	  mother	  and	  
non-­‐steroidal	  anti-­‐inflammatory	  drugs	  (NSAIDs)	  plus	  low	  doses	  of	  prednisone,	  when	  necessary,	  for	  the	  
daughter.	  As	  in	  Crohn's	  disease,	  CARD15/NOD2	  mutation	  is	  believed	  to	  be	  responsible	  for	  the	  





Blau	  syndrome	  (BS)	  is	  a	  rare	  familial	  disease	  characterized	  by	  arthritis,	  uveitis,	  skin	  rash	  and	  granulomatous	  
inflammation	  [1].	  In	  1985	  Blau	  described	  4	  generations	  of	  a	  family	  with	  eleven	  members	  affected	  with	  
granulomatous	  disease	  of	  the	  skin,	  eyes,	  and	  joints.	  Ten	  had	  arthritis;	  two	  had	  skin,	  eye,	  and	  joint	  
involvement;	  one	  had	  skin	  and	  joint	  disease,	  and	  one	  had	  iritis	  only	  [1].	  Observing	  that	  the	  disease	  was	  
transmitted	  as	  an	  autosomal	  dominant	  trait	  and	  only	  partially	  resembling	  sarcoidosis,	  he	  considered	  it	  a	  
new	  syndrome.	  Eleven	  years	  later	  the	  BS	  locus	  was	  mapped	  by	  Tromp	  et	  al.	  by	  genotyping	  72	  of	  the	  74-­‐
member	  pedigree	  with	  dinucleotide-­‐repeat	  markers	  to	  the	  chromosomal	  region	  16q12.1–13	  which	  also	  
contains	  one	  of	  several	  inflammatory	  bowel	  disease	  susceptibility	  loci	  [2].	  Significant	  progress	  was	  further	  
made	  when	  Miceli-­‐Richard	  et	  al.	  observed	  that	  the	  gene	  responsible	  for	  BS	  was	  in	  the	  caspase	  recruitment	  
domain	  (CARD15),	  also	  called	  NOD2	  [3].	  Three	  missense	  mutations	  (R334Q,	  R334W	  and	  L469F)	  were	  
identified	  by	  these	  investigators	  in	  the	  nucleotide-­‐binding	  domain	  (NBD)	  of	  CARD15/NOD2	  in	  four	  French	  
and	  German	  families	  with	  Blau	  syndrome.	  Thus,	  in	  addition	  to	  Crohn's	  disease,	  CARD15/NOD2	  appears	  to	  
be	  involved	  in	  susceptibility	  to	  a	  second	  granulomatous	  disorder	  [4].	  A	  new	  CARD	  15	  mutation	  (E383K)	  has	  
recently	  been	  identified	  in	  a	  family	  followed	  by	  us	  over	  the	  past	  25	  years	  [5].	  As	  this,	  to	  our	  knowledge,	  is	  
the	  only	  diagnosed	  family	  in	  Italy,	  we	  hope	  that	  a	  description	  of	  its	  characteristics	  and	  the	  disease	  course	  
over	  such	  a	  long	  time	  period	  may	  contribute	  to	  better	  understanding	  of	  BS.	  
	  
A	  family	  with	  Blau	  syndrome	  
The	  proband,	  a	  31-­‐year-­‐old	  Caucasian	  woman,	  with	  arthritis	  of	  hands	  and	  feet	  and	  a	  papulonodular	  skin	  
eruption	  was	  referred	  to	  our	  Unit	  in	  1984.	  The	  patient	  reported	  that	  she	  had	  developed	  chronic,	  bilateral	  
uveitis	  and	  glaucoma	  when	  she	  was	  20	  and	  cataracts	  a	  few	  years	  later.	  She	  underwent	  an	  iridectomy	  when	  
she	  was	  24	  and	  a	  cataract	  operation	  7	  years	  later.	  Symmetrical	  arthritis	  involving	  fingers,	  wrists	  and	  feet,	  
and	  skin	  manifestations,	  consisting	  in	  widespread	  papules	  and	  firm	  subcutaneous	  nodules	  on	  the	  
extremities,	  made	  their	  appearance	  during	  adolescence	  and	  intermittently	  thereafter	  although	  well	  
controlled	  by	  non-­‐steroidal	  anti-­‐inflammatory	  drugs	  (NSAIDs).	  
	  
The	  patient	  presented	  with	  asymptomatic,	  diffuse,	  miliary	  brownish	  papule	  and	  firm	  subcutaneous	  
nodules,	  varying	  in	  size	  from	  5	  to	  30	  mm	  in	  diameter,	  on	  the	  dorsa	  of	  hands	  and	  feet	  and	  on	  the	  extensor	  
leg	  surfaces.	  Arthritis	  was	  evident	  on	  the	  bilateral	  metacarpophalangeal	  (MCP)	  and	  proximal	  
interphalangeal	  (PIP)	  joints.	  Neither	  red	  nor	  hot,	  the	  joints	  were	  only	  slightly	  tender	  and	  swollen.	  The	  
bilateral	  1st	  and	  the	  2nd	  metatarsophalangeals	  (MTP)	  of	  the	  feet	  were	  similarly	  involved.	  Camptodactylia	  
(flexion	  contractures	  of	  the	  fingers	  and	  toes)	  was	  not	  present.	  Radiographs	  of	  hands	  and	  feet	  revealed	  only	  
a	  slight	  periosteal	  enlargement	  of	  the	  bone	  and	  a	  chest	  X-­‐ray	  was	  negative.	  Results	  of	  all	  laboratory	  tests	  
including	  inflammatory	  indices	  were	  normal.	  Human	  leukocyte	  antigen	  (HLA)	  typing	  revealed	  A2,	  A3;	  B8,	  
B21;	  DR3,	  DR7.	  Skin	  biopsy	  specimens	  of	  the	  forearms	  were	  processed	  for	  light	  and	  electron	  microscopy	  
examination.	  The	  specimens	  were	  fixed	  in	  formalin	  for	  histologic	  assessment,	  embedded	  in	  paraffin	  and	  
thin	  sections	  were	  obtained	  with	  hematoxylin–eosin,	  PAS,	  PAS-­‐diastase	  and	  Weigert–van	  Gieson.	  Small	  
fragments	  were	  fixed	  in	  glutaraldehyde	  for	  ultrastructural	  examination,	  post-­‐fixed	  in	  osmium	  tetroxide,	  
dehydrated	  in	  ethanol	  solution	  and	  embedded	  in	  epon.	  Semithin	  sections	  were	  stained	  with	  toluidine	  blue	  
and	  observed	  with	  a	  light	  microscope	  and	  ultrathin	  sections	  were	  stained	  with	  uranyl	  acetate	  and	  observed	  
with	  a	  transmission	  electron	  microscope.	  
	  Histology	  revealed	  non-­‐caseating	  granulomas,	  containing	  several	  histiocytes	  and	  multinucleated	  giant	  cells	  
with	  strong	  PAS	  positivity	  and	  rare	  lymphocytes	  and	  eosinophils	  (Fig.	  1a).	  Transmission	  electron	  microscopy	  
showed	  polypoid	  histiocytes	  with	  abundant	  cytoplasm	  containing	  a	  well-­‐developed	  Golgi	  complex	  and	  
endoplasmic	  reticulum,	  profuse	  mitochondria,	  lysosomes	  and	  glycogen	  granules,	  probably	  determining	  PAS	  
positivity	  (Fig.	  1b).	  Pleomorphic	  cytoplasmatic	  inclusions	  were	  found	  in	  a	  few	  cells.	  Some	  collagen	  fibers	  
were	  in	  close	  apposition	  to	  cellular	  membranes,	  often	  surrounded	  by	  a	  cytoplasmatic	  process	  of	  
histiocytes,	  but	  without	  clear	  evidence	  of	  phagocytosis.	  Capillary	  vessels	  with	  swollen	  endothelial	  cells	  due	  
cellular	  infiltrates	  were	  found.	  Due	  to	  the	  limited	  efficacy	  of	  NSAIDs,	  low	  doses	  of	  steroids	  
(methylprednisolone	  4	  mg/day)	  were	  introduced	  and	  are	  continued	  even	  now	  with	  satisfactory	  control	  of	  
all	  disease	  manifestations.	  
	  
	  
One	  month	  after	  her	  first	  examination	  in	  our	  Division,	  the	  proband	  consulted	  us	  about	  her	  five-­‐year-­‐old	  
daughter	  who	  had	  recently	  developed	  skin	  manifestations	  similar,	  although	  less	  severe,	  to	  her	  own.	  No	  
therapy	  was	  prescribed	  at	  that	  time	  as	  the	  entity	  of	  the	  disturbances	  was	  negligible.	  Four	  years	  later,	  
however,	  she	  developed	  arthritis	  with	  slight	  swelling	  of	  all	  fingers	  of	  both	  hands	  and	  moderate	  pain.	  As	  
there	  was	  a	  simultaneous	  worsening	  of	  dermatitis,	  she	  was	  admitted	  to	  the	  Dermatological	  Department	  of	  
the	  University	  of	  Padova.	  All	  routine	  laboratory	  investigations,	  including	  serum	  lipids,	  rheumatoid	  factor	  
and	  antinuclear	  antibodies,	  were	  within	  normal	  limits.	  A	  skin	  biopsy,	  of	  the	  right	  forearm,	  revealed	  some	  
granulomas,	  prevalently	  composed	  of	  PAS	  positive	  histiocytes	  and	  multinucleated	  giant	  cells	  without	  
intracellular	  lipids,	  similar	  to	  those	  observed	  in	  the	  proband.	  BS	  was	  diagnosed,	  but	  no	  specific	  treatment	  
was	  prescribed	  except	  for	  NSAIDs	  which	  were	  to	  be	  taken	  when	  necessary	  for	  a	  few	  days	  time	  for	  pain	  
control.	  
	  
The	  daughter	  was	  admitted	  to	  our	  Rheumatological	  Unit	  when	  she	  was	  12	  because	  of	  painful	  arthritis.	  At	  
the	  physical	  examination	  she	  presented	  asymptomatic	  erythematous	  papules	  on	  the	  extremities,	  in	  
particular	  on	  the	  extensor	  leg	  surfaces,	  symmetric	  arthritis	  involving	  PIP	  and	  MCP	  of	  the	  hands	  (|Fig.	  2)	  and	  
1st	  MTP	  of	  the	  feet,	  which	  were	  swollen,	  tender	  and	  slightly	  warm.	  Radiographs	  revealed	  periarticular	  
swelling	  and	  slight	  space	  narrowing	  of	  the	  PIP	  and	  of	  the	  first	  right	  MTP	  of	  the	  hands.	  Laboratory	  
investigation	  showed	  a	  slightly	  elevated	  erythrocyte	  sedimentation	  rate	  (ESR)	  26	  mm	  1st	  h	  (NV	  <	  20	  mm)	  
and	  policlonal	  hypergammaglobulinemia	  22.5	  %	  (total	  proteins	  7.7	  mg/dl).	  Rheumatoid	  factor	  and	  
antinuclear	  antibodies	  (ANA)	  were	  absent.	  HLA	  typing	  revealed	  A23,	  A24,	  B18,	  B51,	  Bw4,	  DR11,	  DRw52,	  
and	  DQw7.	  An	  electrocardiogram	  was	  normal	  and	  chest	  X-­‐ray	  as	  well	  as	  abdominal	  ultrasound	  were	  
negative.	  An	  ophthalmologic	  examination	  was,	  curiously,	  negative.	  Synovial	  biopsy	  specimens,	  of	  the	  third	  
left	  PIP,	  were	  similar	  to	  the	  skin	  biopsies	  previously	  taken,	  in	  particular	  with	  regards	  to	  the	  non-­‐caseous	  
granulomas.	  The	  diagnosis	  of	  BS	  was	  confirmed	  but	  steroids	  were	  not	  prescribed	  because	  of	  the	  patient's	  
age	  and	  NSAIDs	  were	  begun.	  One	  year	  later,	  when	  the	  patient	  was	  13,	  she	  presented	  bilateral	  anterior	  
uveitis,	  successfully	  treated	  with	  topical	  drugs.	  However,	  some	  weeks	  later,	  since	  arthritis	  and	  skin	  lesions	  
were	  worsening,	  low	  doses	  of	  oral	  steroids	  were	  introduced	  for	  one–two	  week	  cycles,	  obtaining	  a	  good	  
response.	  Continuing	  with	  the	  same	  therapeutic	  regimen	  (mean	  weeks/year	  on	  steroids	  are	  4	  even	  now),	  
the	  disease	  is	  under	  control	  without	  relevant	  impairment	  of	  the	  quality	  of	  life.	  
	  All	  the	  members	  of	  the	  proband's	  family	  underwent	  genetic	  investigation	  two	  years	  ago.	  No	  one	  in	  her	  
family,	  composed	  of	  two	  sisters	  and	  brother,	  her	  husband,	  and	  her	  other	  daughter,	  showed	  symptoms	  of	  




To	  our	  knowledge,	  BS	  has	  been	  observed	  until	  now	  in	  154	  persons	  belonging	  to	  41	  families	  (Table	  1)	  [1],	  
[2],	  [3],	  [4],	  [5],	  [6],	  [7],	  [8],	  [9],	  [10],	  [11],	  [12],	  [13],	  [14],	  [15],	  [16],	  [17],	  [18],	  [19],	  [20],	  [32],	  [33]	  and	  [34]	  
and	  in	  4	  sporadic	  cases	  [21],	  [22]	  and	  [23].	  Joint	  discomfort	  is	  the	  most	  frequently	  reported	  symptom,	  
followed	  by	  skin	  and	  eye	  disturbances.	  Camptodactyly,	  considered	  a	  common	  finding	  in	  BS	  by	  Blau	  [1],	  and	  
subsequently	  described	  in	  some	  cases,	  was	  not	  a	  symptom	  in	  our	  patients.	  The	  most	  frequent	  joint	  
involvement	  in	  BS	  is	  inflammatory	  arthritis,	  with	  moderate	  redness,	  warmth	  and	  tenderness,	  associated	  
with	  synovial	  cysts	  particularly	  affecting	  wrists	  and	  dorsa	  of	  the	  hands,	  and	  tenosynovitis,	  which	  contributes	  
to	  the	  frequently	  observed	  periarticular	  swelling.	  Arthritis	  symmetrically	  involving	  wrists,	  MCP,	  1st	  MTP,	  PIP	  
of	  hands	  and	  feet,	  ankles	  and	  rarely	  elbows,	  has	  a	  chronic	  evolution	  in	  these	  patients	  and	  may	  lead	  to	  
deformity	  of	  fingers	  and	  to	  wrist	  ankylosis.	  Joint	  involvement	  almost	  always	  has	  a	  juvenile	  onset,	  
presenting	  as	  painless	  cysts	  on	  the	  back	  of	  feet	  and	  wrists	  which	  may	  evolve	  into	  mild	  “boutonniere	  finger	  
deformities”	  [12]	  and	  [24].	  Traditional	  X-­‐rays	  show	  the	  typical	  deformities	  of	  periarticular	  swelling	  and,	  at	  
times,	  joint	  space	  narrowing	  [12]	  and	  [24].	  Although	  deformities	  are	  frequently	  seen,	  especially	  when	  there	  
is	  camptodactylia,	  bone	  erosion	  has	  never	  been	  reported.	  
	  
Various	  skin	  manifestations	  have	  been	  described	  and	  can	  be	  classified	  as	  two	  main	  types:	  a	  papulonodular	  
tender	  brownish	  rash	  and	  multiple,	  firm,	  subcutaneous	  plaques	  only	  apparent	  on	  palpation.	  In	  the	  proband	  
and	  her	  daughter,	  the	  principal	  skin	  manifestation	  was	  a	  papulonodular,	  painless	  often	  diffuse	  rash.	  It	  has	  
been	  seen	  that	  its	  onset	  is	  almost	  always	  during	  childhood.	  As	  it	  is	  often	  mild	  and	  regresses	  spontaneously	  
it	  can	  even	  go	  unnoticed.	  In	  some	  cases	  the	  eruptions	  are	  described	  as	  erythematous,	  in	  other	  intermittent	  
and/or	  generalized	  [17].	  A	  skin	  biopsy	  shows	  non-­‐caseating	  granulomas	  with	  multinucleated	  giant	  cells	  [1],	  
[2],	  [6],	  [8]	  and	  [14].	  The	  electron	  microscopy	  may	  reveal	  “comma-­‐shaped	  bodies”	  in	  epithelioid	  cells	  [14]	  
which	  seem	  to	  be	  a	  marker	  for	  BS	  [12]	  and	  [14].	  
	  
Eye	  involvement,	  often	  the	  most	  severe	  aspect	  of	  BS	  [1],	  [15],	  [18]	  and	  [20],	  may	  present	  as	  granulomatous	  
anterior	  frequently	  bilateral	  uveitis,	  which	  can	  evolve	  into	  a	  cataract	  and	  band	  keratopathy,	  frequently	  
requiring	  surgery	  [18].	  Other	  findings	  include	  vitritis,	  granulomatous	  disks,	  and	  bilateral	  disseminated	  
chorioretinal	  lesions	  that	  are	  surrounded	  by	  retinal	  hemorrhages	  and	  progressive	  subretinal	  fibrosis	  [1],	  [2]	  
and	  [18].	  Fundus	  modifications	  at	  times	  resemble	  those	  in	  sarcoid	  uveitis	  [18].	  
	  
Involvement	  of	  other	  organs	  has	  rarely	  been	  described	  in	  BS.	  In	  particular,	  in	  contrast	  to	  sarcoidosis	  [24],	  
the	  lungs	  are	  seldom	  affected.	  The	  only	  visceral	  involvement	  that	  has	  been	  reported	  until	  now	  are	  hepatic	  
[10],	  or	  renal	  granulomatoses	  [13],	  ichthyosis	  [19]	  and,	  on	  the	  basis	  of	  a	  vast	  study	  by	  Wang	  X	  et	  al.,	  large	  
vessel	  arteritis	  and	  cranial	  neuropathy	  [14].	  
	  
Some	  authors	  have	  recently	  proposed	  that	  early-­‐onset	  sarcoidosis	  may	  represent	  the	  sporadic	  counterpart	  
of	  BS,	  sharing	  an	  identical	  phenotype	  and	  associated	  with	  mutations	  of	  CARD15	  in	  50–90%	  of	  cases	  [25].	  
Both	  pathologies	  have	  been	  included	  in	  the	  “pediatric	  granulomatous	  arthritis	  family”	  and	  an	  international	  
registry	  was	  established	  in	  the	  spring	  of	  2005.	  
	  
Due	  to	  its	  rarity	  and	  the	  variations	  in	  the	  severity	  and	  evolution	  of	  its	  expressions,	  treatment	  of	  BS	  is	  based	  
on	  empiric	  experience.	  The	  major	  concern	  regards	  eye	  involvement,	  which	  may,	  at	  times,	  be	  severe	  [1],	  [5]	  
and	  [18].	  At	  the	  quiescent	  stage,	  low-­‐dose	  glucocorticoids	  are	  generally	  satisfactory,	  as	  was	  the	  case	  in	  the	  
proband	  we	  treated	  [15].	  High	  doses	  of	  glucocorticoids	  are,	  however,	  necessary	  in	  some	  acute	  stages.	  Since	  
disease	  onset	  is	  often	  during	  childhood	  its	  long	  term	  use	  especially	  at	  high	  doses,	  may	  be	  problematic.	  
Additional	  treatment	  with	  immunosuppressive	  agents,	  such	  as	  methotrexate	  and	  azathioprine,	  has	  been	  
attempted	  in	  the	  past.	  So-­‐called	  “biologic”	  anti-­‐cytokine	  agents	  such	  as	  infliximab,	  a	  tumour	  necrosis	  factor	  
(TNF)-­‐α	  inhibitor	  and	  anakinra,	  an	  anti-­‐IL1,	  have	  recently	  been	  demonstrated	  to	  be	  effective	  in	  refractory	  
cases	  [21]	  and	  [31].	  
	  
Genetic	  aspects	  
Once	  the	  disease	  and	  its	  familial	  transmission	  were	  described	  by	  Blau	  [1]	  and	  the	  locus	  was	  mapped	  by	  
Tromp	  et	  al.	  on	  the	  chromosomal	  region	  16q12.1–13	  [2],	  the	  most	  significant	  progress	  in	  the	  study	  of	  BS	  
was	  made	  by	  Miceli-­‐Richard	  et	  al.	  who	  reported	  that	  the	  responsible	  gene	  is	  in	  the	  caspase	  recruitment	  
domain	  (CARD15)	  [3].	  These	  authors	  identified	  three	  missense	  mutations	  (R334Q,	  R334W	  and	  L469F)	  in	  the	  
nucleotide-­‐binding	  domain	  (NBD)	  of	  CARD15/NOD2	  in	  four	  French	  and	  German	  families	  with	  Blau	  
syndrome.	  The	  two	  most	  frequent	  mutations	  in	  the	  other	  families	  were	  those	  located	  in	  codon	  334.	  An	  
additional	  CARD15	  mutation	  (E383K)	  has	  recently	  been	  identified	  in	  the	  proband's	  family	  described	  here	  [5]	  
and	  sporadic	  de	  novo	  mutations	  have	  subsequently	  been	  reported	  [21],	  [22]	  and	  [23].	  
	  
CARD	  15/NOD2	  encodes	  a	  1.040	  amino-­‐acid	  protein	  that	  structurally	  consists	  in	  two	  N-­‐terminal	  CARDs	  
linked	  to	  a	  NBD,	  and	  multiple	  leucine-­‐rich	  repeat	  (LRR)	  at	  its	  carboxyl	  terminal	  region	  [3],	  [5]	  and	  [26].	  
CARD15	  is	  mapped	  to	  chromosome	  16q12,	  is	  expressed	  predominantly	  in	  a	  monocytic	  lineage,	  and	  may	  
interact	  with	  lipopolysaccharide	  (LPS)	  structures	  by	  its	  LRR	  domains	  to	  activate	  nuclear	  factor	  kappa-­‐B	  (NF-­‐
kB).	  It	  is	  interesting	  that	  mutations	  involving	  LRR	  appear	  to	  predispose	  to	  Crohn's	  disease,	  while	  those	  in	  
the	  NBD	  are	  unique	  to	  BLAU	  syndrome	  [2]	  and	  [3].	  CARD15/NOD2,	  a	  member	  of	  the	  CED4/APAF1	  family	  of	  
apoptosis	  regulators,	  binds	  directly	  to	  a	  muramyl	  dipeptide	  (MDP)	  that	  is	  common	  to	  all	  bacteria	  [27],	  
leading	  to	  NF-­‐kB	  activation.	  The	  majority	  of	  the	  CD	  associated	  variants	  of	  CARD15/NOD2,	  localized	  in	  the	  
LRRs,	  result	  in	  defective	  NF-­‐kB	  activation	  and	  bacterial	  clearance	  [28]	  and	  [29].	  All	  CARD15/NOD2	  
mutations	  described	  until	  now	  in	  BS	  are	  located	  in	  the	  region	  encoding	  the	  NBD	  [3],	  [5]	  and	  [14].	  Although	  
bacteria's	  role	  in	  its	  pathogenesis	  has	  not	  been	  demonstrated,	  BS	  has	  recently	  been	  found	  to	  be	  associated	  
with	  a	  distinctive	  mutation	  in	  CARD15/NOD2,	  which	  encodes	  for	  an	  intracellular	  toll-­‐like	  receptor	  [30].	  
Studying	  the	  host	  cell	  interaction	  with	  bacterial	  challenge	  (Salmonella	  typhimurium)	  in	  U937	  cells	  
expressing	  wild	  type	  human	  NOD2	  (NOD2wt),	  mutant	  NOD2	  (NOD2Blau)	  or	  vector	  control	  (VC),	  Kim	  et	  al.	  
found	  that	  the	  invasion	  of	  target	  cells	  was	  diminished	  in	  the	  presence	  of	  NOD2Blau	  and	  that	  the	  expression	  
of	  TNF-­‐α	  mRNA	  was	  enhanced	  in	  all	  cell	  lines	  following	  bacterial	  invasion.	  NOD2Blau	  was,	  however,	  
associated	  with	  a	  more	  rapid	  decline	  in	  TNF-­‐α	  expression.	  The	  kinetics	  of	  intracellular	  bacteria	  clearance	  
indicated	  a	  relative	  defect	  in	  NOD2Blau	  compared	  to	  controls.	  
	  
Although	  mutations	  conferring	  susceptibility	  to	  BS	  occur	  in	  a	  domain	  (NBD)	  independent	  of	  LRR	  interactions	  
which	  are	  thought	  to	  induce	  defective	  clearance	  of	  bacteria	  [28]	  and	  [29],	  it	  has	  been	  observed	  that	  
CARD15/NOD2	  mutation	  of	  codon	  334	  seems	  to	  cause	  a	  four-­‐fold	  higher	  activation	  of	  NF-­‐kB,	  compared	  to	  
wild	  type	  alleles	  [5]	  and	  [35].	  
	  
Take-­‐home	  messages	  
•	  Blau	  syndrome	  is	  a	  prototype	  of	  autoinflammatory	  syndrome	  without	  fever	  and	  detectable	  acute	  phase	  
reaction,	  which	  may	  be	  useful	  to	  better	  understand	  mechanisms	  and	  role	  of	  non-­‐caseating	  granuloma	  in	  
inflammation.	  
•	  The	  expanding	  clinical	  heterogeneity	  of	  the	  pediatric	  granulomatous	  diseases	  syndromes	  and	  the	  high	  
prevalence	  of	  sporadic	  cases	  should	  alert	  clinicians	  to	  the	  possible	  genetic	  basis	  of	  the	  condition	  and	  
support	  the	  inclusion	  of	  DNA	  analysis	  as	  a	  diagnostic	  test.	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Fig. 1.	   
Skin biopsy showing (a) the presence of non-caseating granulomas, containing several histiocytes 
and multinucleated giant cells with strongly PAS positivity and rare lymphocytes and eosinophils; 
electron microscopy showing (b) polipoid hystiocytes with abundant cytoplasm containing 
lysosomes and glicogen granules.	  
 
 
Fig. 2.	   



















Blau	  (1985)	   1	   11	   4	   10	   3	   3	   None	  
Jabs	  (1985)	   1	   4	   3	   4	   No	   3	   None	  
Pastores	  (1990)	   1	   3	   2	   3	   2	   3	   None	  
De	  Chadarévian	  (1993)	   1	   2	   2	   2	   2	   2	   None	  
Hafner	  (1993)	   1	   2	   2	   2	   1	   1	   None	  
Moraillon	  (1996)	   1	   2	   2	   2	   1	   No	   None	  
Saini	  (1996)	   1	   3	   2	   3	   1	   1	   Hepatic	  granulom.	  
Tromp	  (1996)	   1	   16	   4	   13	   8	   6	   Not	  evaluated	  
Scerri	  (1996)	   1	   2	   2	   2	   2	   2	  
None/Neurological	  
inv.	  
Manouvier-­‐Hanu	  (1998)	   1	   4	   2	   4	   2	   2	   None	  
Ting	  (1998)	   1	   3	   2	   2	   3	   No	   Renal	  granulom.	  
Miceli-­‐Richard	  (2001)	   4	   11	   2	   9	   7	   5	   None	  




Latkany	  (2002)	   8	   16	   3	   15	   9	   16	   None	  
Ewida	  (2002)	   1	   4	   2	   4	   4	   2	   None	  
Alonso	  (2003)	   1	   4	   2	   4	   4	   2	   None	  
Kurokawa	  (2003)	   1	   3	   2	   3	   2	   3	   None	  
Masel	  (2005)	   1	   1	   1	   1	   1	   1	   Ichthyosis	  
Van	  Duist	  (2005)	   1	   2	   2	   1	   1	   1	   None	  
Snyers	  and	  Dahan	  
(2006)	   1	   3	   2	   3	   2	   2	   None	  
Shaffer	  (2007)	   1	   4	   3	   0	   2	   3	   None	  
Becker	  (2007)	   1	   4	   2	   4	   0	   3	   Pneumonitis	  
	  
